Selective HDAC6 inhibition offers the most feasible therapeutic approach among the seven hypotheses, with favorable druggability characteristics including available crystal structures, viable selective inhibitors (ACY-1215/Ricolinostat, Tubastatin A), and demonstrated tolerability in Phase I/II oncology trials. HDAC6's cytoplasmic localization avoids the nuclear toxicity concerns of pan-HDAC inhibition, and its role in regulating microtubule stability and Hsp90 function provides multiple benefic
Selective HDAC6 inhibitors (T-518, Tubastatin A, ACY-1215) simultaneously increase α-tubulin acetylation to restore microtubule stability disrupted by tau pathology, reduce tau hyperphosphorylation through improved vesicular transport, and enhance autophagic clearance of aggregated tau. The selectivity of HDAC6 over other HDACs avoids broad transcriptional dysregulation.
Verdict Summary
10/10
dimensions won
HDAC6 Selective Inhibition to Restore Ac
0/10
dimensions won
HDAC6 Inhibition for Dual Restoration of
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.72
0.58
Evidence
0.68
0.52
Novelty
0.55
0.42
Feasibility
0.75
0.48
Impact
0.70
0.65
Druggability
0.82
0.62
Safety
0.65
0.45
Competition
0.70
0.55
Data
0.72
0.60
Reproducible
0.78
0.48
Score Breakdown
Dimension
HDAC6 Selective Inhibition to
HDAC6 Inhibition for Dual Rest
Mechanistic
0.720
0.580
Evidence
0.680
0.520
Novelty
0.550
0.420
Feasibility
0.750
0.480
Impact
0.700
0.650
Druggability
0.820
0.620
Safety
0.650
0.450
Competition
0.700
0.550
Data
0.720
0.600
Reproducible
0.780
0.480
Evidence
HDAC6 Selective Inhibition to Restore Acetylation Balance an
Supporting Evidence
MGCD0103 HDAC inhibitor co-ameliorates cognitive deficits and reduces tau phosphorylationPMID:29978554
HDAC6 regulates tubulin acetylation and microtubule dynamicsPMID:30407786
Structure-based drug design recommends HDAC6 inhibitors to attenuate microtubule-associated tau pathogenesisPMID:30407786
Increased acetylation of microtubules rescues human tau-induced microtubule defectsPMID:28819043
HDAC6 knockout mice are viable with mild phenotypes, indicating favorable safety profile for selective inhibition
Contradicting Evidence
No HDAC6 inhibitor has completed Phase II trials for neurodegeneration specifically
HDAC6 inhibition modifies tau inclusion body formation but may impair autophagic clearancePMID:25434725
Tau antibody failures (Semorinemab TANGO trial) set negative precedent for protein-targeting approaches
HDAC6 Inhibition for Dual Restoration of Microtubule Stabili
Supporting Evidence
T-518, an orally active selective HDAC6 inhibitor, shows therapeutic potential in AD and tauopathy mouse models with favPMID:34326423
Tubastatin A/ACY-1215 improves cognition in AD transgenic mice by promoting tubulin acetylation, reducing Aβ production,PMID:24844691
HDAC6 is a major regulator of MT acetylation status, and pharmacological HDAC6 inhibition improves axonal function and sPMID:34326423
HDAC6 modulates tau inclusion body formation and impairs autophagic clearance in ways that promote pathological tau remoPMID:25434725
Tau itself is an inhibitor of deacetylase HDAC6 function, creating a pathological feedback loop where tau accumulation fPMID:19457097
Contradicting Evidence
HDAC6 knockout mice exhibit cognitive impairment rather than enhancement, contradicting the therapeutic hypothesis
Tubastatin A demonstrates poor brain penetration in pharmacokinetic studies
ACY-1215 (Ricolinostat) clinical development has stalled in cancer indications due to combination toxicity concerns
HDAC6 Inhibition for Dual Restoration of Microtubu
4 rounds · quality: 0.50
Theorist
# Novel Therapeutic Hypotheses: Disease-Specific Tau PTM Targets
## Hypothesis 1: P300/CBP Acetyltransferase Inhibition to Block K280 Acetylation While Preserving Physiological Acetylation
**Targe...
Skeptic
# Critical Evaluation of Disease-Specific Tau PTM Therapeutic Hypotheses
## Hypothesis 1: P300/CBP Acetyltransferase Inhibition
### Specific Weaknesses in the Evidence
**Enzymatic Specificity Gap...
Domain Expert
# Domain Expert Evaluation: Disease-Specific Tau PTM Drug Targets
## Executive Summary
Of the seven hypotheses, **none currently meet all criteria for an optimal therapeutic target**: disease-spec...